Table 4.
Meta-analysis results for miRNA expression in colorectal cancer
| miRNA | Survival analysis | Articles | Studies included | HR | 95% CI | Figure | P-value | Heterogeneity (Higgins’s I2) | Patients, n |
|---|---|---|---|---|---|---|---|---|---|
| High miR21 | OS | 3 | 4, 5, 7 | 1.56 | 0.47–5.23 | 2 | 0.47 | 85.2%, P<0.01 | 616 |
| High miR21 | DFS | 3 | 4, 6, 7 | 1.39 | 0.49–3.96 | 2 | 0.53 | 84.4%, P<0.01 | 480 |
| High miR92a | OS | 2 | 10, 13 | 2.11 | 0.59–7.61 | 2 | 0.25 | 81.6%, P=0.02 | 240 |
| High miR141 | OS | 2 | 14, 19 | 2.52 | 1.68–3.77 | 2 | <0.01 | 0.0%, P=0.87 | 426 |
| High miR200b | OS | 2 | 14, 16 | 1.28 | 0.75–2.19 | 2 | 0.36 | 88.8%, P<0.01 | 696 |
| High miR203 | OS | 2 | 24, 25 | 0.99 | 0.22–4.37 | 2 | 0.99 | 91.4%, P<0.01 | 366 |
| High miR21 | OS | 13 | 5, 60–68, 70–73 | 1.31 | 1.12–1.53 | 3A | <0.01 | 65.3%, P<0.01 | 2,861 |
| High miR21 | OSa | 8 | 5, 60, 63, 65, 66, 68, 71, 73 | 1.47 | 1.16–1.87 | 3A | <0.01 | 71.7%, P<0.01 | 2,372 |
| High miR21 | DFS | 7 | 58–61, 67, 68, 70 | 1.64 | 1.11–2.41 | 3D | 0.01 | 79.2%, P<0.01 | 554 |
| High miR21 | RFS/CSS/MFS/PFS | 5 | 63, 64, 69, 71, 73 | 1.33 | 1.06–1.67 | 3D | 0.01 | 48.6%, P=0.07 | 1,787 |
| High miR21 | OS, adjustedb | 1.13 | 0.96–1.34 | 4B | 0.15 | 71.6%, P<0.01 | |||
| High miR106a | OS | 5 | 49, 67, 112–114 | 1.31 | 0.72–2.36 | 5 | 0.38 | 62.2%, P=0.03 | 403 |
| High miR106a | DFS/MFS | 5 | 49, 64, 67, 11, 113 | 1.14 | 0.55–2.36 | 5 | 0.72 | 75.8%, P<0.01 | 519 |
| High miR125b | OS | 5 | 33, 35, 106, 112, 119 | 1.43 | 0.83–2.47 | 5 | 0.19 | 74.6%, P<0.01 | 857 |
| Low miR126 | OS | 5 | 120, 122–125 | 1.55 | 1.24–1.93 | 6 | <0.01 | 1.2%, P=0.40 | 948 |
| Low miR126 | PFS/RFS/CSS | 3 | 120–122 | 1.72 | 0.95–3.10 | 6 | 0.07 | 75.2%, P=0.02 | 732 |
| Low miR143 | DFS/CSS/PFS | 3 | 59, 151, 153 | 1.00 | 0.47–2.13 | 6 | 1.00 | 77.7%, P<0.01 | 230 |
| Low miR143 | OS | 3 | 112, 150, 152 | 1.69 | 0.94–3.04 | 6 | 0.08 | 0.0%, P=0.69 | 159 |
| Low miR145 | OS | 4 | 33, 150, 155, 156 | 1.68 | 0.55–5.12 | 7 | 0.36 | 85.4%, P<0.01 | 254 |
| Low miR145 | MFS/DFS | 2 | 64, 156 | 1.23 | 0.30–5.06 | 7 | 0.77 | 85.1%, P<0.01 | 253 |
| High miR181a | OS | 3 | 165, 166, 168 | 1.52 | 1.26–1.83 | 7 | <0.01 | 0.0%, P=0.45 | 665 |
| High miR181a | DFS/CSS/PFS/RFS | 3 | 18, 165, 67 | 1.17 | 0.53–2.59 | 7 | 0.69 | 84.0%, P<0.01 | 309 |
| High miR224 | OS | 4 | 206, 209, 211, 212 | 2.12 | 1.04–4.34 | 8 | 0.04 | 80.9%, P<0.01 | 740 |
| High miR224 | DFS/MFS | 4 | 206, 210–212 | 1.43 | 0.23–8.77 | 8 | 0.70 | 90.6%, P<0.01 | 294 |
| High miR429 | OS | 5 | 146, 228–231 | 1.00 | 0.39–2.58 | 8 | 1.00 | 88.7%, P<0.01 | 467 |
Notes:
a
Multiple-covariate analysis;
b
adjusted with trim-and-fill method.
Abbreviations: OS, overall survival; DFS, disease-free survival; RFS, recurrence-free survival; CSS, cause-specific survival; MFS, metastasis-free survival; PFS, progression-free survival.